Biohaven Analyst Price Targets

Wall Street analyst price targets and consensus rating for Biohaven (BHVN).

Price Target Range — 12 Quarters

Analyst Consensus — 18 Analysts

1S.Buy

11Buy

5Hold

1Sell

Consensus RatingBuy# Analysts18Avg. Consensus PT$33Upside to Avg. PT+160.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 10, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Neutral	$10
Sep 8, 2026	RBC Capital	Leonid Timashev	Downgrade	Outperform→Sector Perform	$23→$19
Aug 12, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$18→$19
Aug 11, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$22→$23
Jun 29, 2026	B of A Securities	Jason Gerberry	Downgrade	Neutral→Underperform	$12→$11
May 26, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Neutral	$10
May 13, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$21→$18
May 5, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$23→$22
Apr 2, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$14→$17
Mar 11, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$15→$30
Mar 4, 2026	HC Wainwright & Co.	Douglas Tsao	PT Cut	Neutral	$11→$10
Mar 3, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$22→$23
Jan 21, 2026	RBC Capital	Leonid Timashev	Upgrade	Sector Perform→Outperform	$9→$22
Jan 6, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$26→$21
Dec 26, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Neutral	$11
Dec 3, 2025	HC Wainwright & Co.	Douglas Tsao	Downgrade	Buy→Neutral	$30→$11
Nov 26, 2025	UBS	Ashwani Verma	Downgrade	Buy→Neutral	$26→$11
Nov 20, 2025	JP Morgan	Tessa Romero	PT Cut	Overweight	$47→$15
Nov 18, 2025	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$54→$26
Nov 18, 2025	BTIG	Thomas Shrader	Maintained	Buy	$16

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and maintains $10 price target.

Benzinga Newsdesk

PRO
RBC Capital Downgrades Biohaven to Sector Perform, Lowers Price Target to $19

RBC Capital analyst Leonid Timashev downgrades Biohaven (NYSE:BHVN) from Outperform to Sector Perform and lowers the price target from $23 to $19.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises the price target from $18 to $19.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises the price target from $22 to $23.

Benzinga Newsdesk

Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out

Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahead of key epilepsy trial data.

Vandana Singh

PRO
B of A Securities Downgrades Biohaven to Underperform, Lowers Price Target to $11

B of A Securities analyst Jason Gerberry downgrades Biohaven (NYSE:BHVN) from Neutral to Underperform and lowers the price target from $12 to $11.

Benzinga Newsdesk

Biohaven Ltd

Biohaven Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target

PRO
RBC Capital Downgrades Biohaven to Sector Perform, Lowers Price Target to $19

PRO
Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19

PRO
RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23

Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out

PRO
B of A Securities Downgrades Biohaven to Underperform, Lowers Price Target to $11

People Also Watch

People Also Watch

Biohaven Ltd

Biohaven Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target

PRORBC Capital Downgrades Biohaven to Sector Perform, Lowers Price Target to $19

PROMorgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19

PRORBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23

Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out

PROB of A Securities Downgrades Biohaven to Underperform, Lowers Price Target to $11

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target

PRO
RBC Capital Downgrades Biohaven to Sector Perform, Lowers Price Target to $19

PRO
Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19

PRO
RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23

PRO
B of A Securities Downgrades Biohaven to Underperform, Lowers Price Target to $11